Rhythm Pharmaceuticals Stock Earnings Reports

Rhythm Pharmaceuticals reported Q1 2026 results and provided an update on commercial progress and pipeline milestones. Key commercial highlights: global net revenues were $60.1M (5% sequential growth), with 61% from the U.S.; continued growth in patients on reimbursed therapy (+8% QoQ); and an encouraging early U.S. launch for IMCIVREE in acquired hypothalamic obesity (AHO) with more than 150 start forms in ~6 weeks, ~110 unique prescribers (~80% new to IMCIVREE) and early payer approvals. Europe received CHMP/European Commission marketing authorization for AHO and Japan’s PMDA has accepted an NDA with anticipated approval/launch by end of 2026. The company is expanding commercial infrastructure for AHO (U.S. salesforce from 16 to 42 reps; ~50 employees in Japan) and continuing life-cycle work including CMC and bioequivalence efforts for a new formulation and planning a Phase III for bivamelagon (RM-718) aimed to start by end of 2026. R&D and SG&A increased as Rhythm scales (Q1 operating expenses totaled ~$105.3M GAAP; non-GAAP operating expense guidance for FY2026 remains $385–415M). Financial position: $341M in cash, equivalents and short-term investments; management expects this to fund operations for at least 24 months. Upcoming data and milestones: potential Endocrine meeting presentation of 6-month PWS data, midyear RM-718 data, and Part C HO results targeted for the Q2 earnings call.